• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, October 10, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Pathogens may evade immune response with metal-free enzyme required for DNA replication

Bioengineer by Bioengineer
October 18, 2018
in Health
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram
IMAGE

Credit: Gavin Palowitch, Penn State

Some bacterial pathogens, including those that cause strep throat and pneumonia, are able to create the components necessary to replicate their DNA without the usually required metal ions. This process may allow infectious bacteria to replicate even when the host's immune system sequesters iron and manganese ions in an attempt to slow pathogen replication. A new study, which appears in the journal Proceedings of the National Academy of Science, describes a novel subclass of metal-free ribonucleotide reductase enzymes used by these bacteria, an understanding of which could drive the development of new, more effective antibiotics.

"Every organism uses ribonucleotide reductase (RNR) enzymes to make the nucleotide building blocks needed for DNA replication and repair," said Amie Boal, assistant professor of chemistry and of biochemistry and molecular biology at Penn State and the lead author of the paper. "Because RNRs are essential, they are validated drug targets for some cancers and viral infections, but they have not yet been exploited as drug targets in pathogenic bacteria. One of the goals of our work is to better understand the cofactors required by RNRs to function, which will hopefully inspire the creation of new, potent antimicrobial drugs that can inhibit the enzyme."

RNRs perform very complex chemistry to convert ribonucleotides–the building blocks of RNA, which are present in the cell–into deoxyribonucleotides–the building blocks of DNA. All known RNRs used during aerobic metabolism require a metal ion cofactor, which acts as a powerful oxidizing agent to drive the conversion. In their new study, the team of researchers have now identified and described a new subclass of RNR that is capable of performing this process without the aid of a metal ion in the bacterial pathogens that cause strep throat, pneumonia, rheumatic fever, and other diseases.

"Requiring a trace-metal cofactor is the Achilles heel of an RNR, especially in pathogenic bacteria," said Gavin Palowitch, Ph.D. candidate in biochemistry, microbiology, and molecular biology at Penn State and coauthor of the study. "When a pathogen invades your body, one of the things that your immune system can do is try to deprive it of iron and manganese ions in an attempt to slow reproduction. If you have a way to make DNA that doesn't rely as much on a metal cofactor, that's a novel tactic for evading the immune response."

The researchers showed that this new subclass of RNR is able to use a modified amino acid instead of a metal ion as the oxidizing agent that drives the creation of DNA nucleotides. It remains unknown whether a metal is required for initial synthesis of the modified amino acid and then lost. But the study establishes that the modification does require a separate protein for its installation.

"The need for another activating protein is critical for thinking about inhibiting this enzyme with antibiotic drugs," said Boal. "Protein-protein interactions are really attractive targets for disruption by small molecule therapeutics."

###

In addition to Boal and Palowitch, the research team includes Elizabeth J. Blaesi, Kai Hu, Amelia J. Kim, Hannah R. Rose, Rahul Alapati, Tatiana N. Laremore, Carsten Krebs, Alexey Silakov, J. Martin Bollinger Jr., and Benjamin D. Allen at Penn State; Marshall G. Lougee, Hee Jong Kim, and Megan L. Matthews at the University of Pennsylvania; and Alexander T. Taguchi, Kong Ooi Tan, and Robert G. Griffin at the Massachusetts Institute of Technology.

The research was funded by the Searle Scholars Program and the U.S. National Institutes of Health. Additional support was provided by the Penn State Huck Institutes of the Life Sciences.

Media Contact

Sam Sholtis
[email protected]
814-865-1390
@penn_state

http://live.psu.edu

Original Source

http://science.psu.edu/news-and-events/2018-news/Boal10-2018 http://dx.doi.org/10.1073/pnas.1811993115

Share12Tweet7Share2ShareShareShare1

Related Posts

Revolutionary Nanoparticles Enhance Inner Ear Drug Delivery

October 10, 2025

High-Voltage Electrocution: SEM-EDS Reveals Wound Insights

October 10, 2025

Linking COPD, Cardiovascular Admissions to Referral Compliance

October 10, 2025

Impact of Nurses’ Well-being on Organ Donation Attitudes

October 10, 2025
Please login to join discussion

POPULAR NEWS

  • Sperm MicroRNAs: Crucial Mediators of Paternal Exercise Capacity Transmission

    1186 shares
    Share 474 Tweet 296
  • New Study Reveals the Science Behind Exercise and Weight Loss

    101 shares
    Share 40 Tweet 25
  • New Study Indicates Children’s Risk of Long COVID Could Double Following a Second Infection – The Lancet Infectious Diseases

    96 shares
    Share 38 Tweet 24
  • Ohio State Study Reveals Protein Quality Control Breakdown as Key Factor in Cancer Immunotherapy Failure

    82 shares
    Share 33 Tweet 21

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Revolutionary Nanoparticles Enhance Inner Ear Drug Delivery

High-Voltage Electrocution: SEM-EDS Reveals Wound Insights

Linking COPD, Cardiovascular Admissions to Referral Compliance

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 63 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.